MF

Michel Finance

Venture Partner at Truffle Capital

Paris, France

About

Michel is CEO and Board member of Theradiag, a company specialized in biotherapy monitoring and diagnostic. Prior to joining Theradiag, Michel was executive VP of Neovacs and Flamel Technologies, both biotech companies listed on Alternext and Nasdaq respectively, CEO of Carmat, an innovative company developing a total artificial heart and listed on Alternext and co-founded by Truffle Capital, Senior Vice President of the Aventis Group, one of the leading pharmaceutical companies in the world, and Senior Vice President and CFO of Sanofi Pasteur, a world leader in vaccines. Michel is also a Director of France Biotech, the French association of entrepreneurs in the biotech sector, and of Carmat and Neovacs. Michel graduated from EM Lyon and is a Certfied Public Accountant. Chevalier de l’ordre national du Mérite.

Position in the VCSift Database

  • 15 investors at Truffle Capital are tracked.
  • 421 investors hold the Venture Partner role in VCSift. Michel Finance is one of them.
  • 2,833 investors are based in Paris, Ile-de-France, France.

Data sourced from 410,343 investor profiles. Updated July 2026.

Investment Focus

Contact Information

em••••@example.com
linkedin.com/in/••••••••

Unlock contact details with a VCSift subscription

Unlock Contact

Already subscribed? Log in

Find more investors like Michel

Search Investors